Cargando…
The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization
INTRODUCTION: We evaluated incidence, prevalence, costs, and healthcare utilization associated with systemic lupus erythematosus (SLE) in patients in Germany. METHODS: Adult patients with SLE were identified from the German Betriebskrankenkassen (BKK) health insurance fund database between 2009 and...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991067/ https://www.ncbi.nlm.nih.gov/pubmed/33544369 http://dx.doi.org/10.1007/s40744-021-00277-0 |
_version_ | 1783669180248096768 |
---|---|
author | Schwarting, Andreas Friedel, Heiko Garal-Pantaler, Elena Pignot, Marc Wang, Xia Nab, Henk Desta, Barnabas Hammond, Edward R. |
author_facet | Schwarting, Andreas Friedel, Heiko Garal-Pantaler, Elena Pignot, Marc Wang, Xia Nab, Henk Desta, Barnabas Hammond, Edward R. |
author_sort | Schwarting, Andreas |
collection | PubMed |
description | INTRODUCTION: We evaluated incidence, prevalence, costs, and healthcare utilization associated with systemic lupus erythematosus (SLE) in patients in Germany. METHODS: Adult patients with SLE were identified from the German Betriebskrankenkassen (BKK) health insurance fund database between 2009 and 2014. SLE incidence and prevalence were calculated for each year and extrapolated (age and sex adjusted) to the German population. The 2009 SLE population was followed through 2014. Healthcare utilization and costs for patients with SLE were calculated and compared with controls matched by age, sex, and baseline Charlson Comorbidity Index scores. RESULTS: This analysis included 1160 patients with SLE. Estimated SLE incidence between 2009 and 2014 ranged from 4.59 to 6.89 per 100,000 persons and prevalence ranged from 37.32 to 47.36 per 100,000. SLE incidence in Germany in 2014 was 8.82 per 100,000 persons; prevalence was 55.80 (corrected for right-censored data). At baseline, 12.8, 41.7, and 45.5% of patients were categorized as having mild, moderate, and severe SLE, respectively. Patients with SLE had greater mean (standard deviation [SD]) annual medical costs compared with matched controls 1 year after index diagnosis (€6895 [14,424] vs. €3692 [3994]; P < 0.0001) and in subsequent years. Patients with moderate or severe SLE had significantly more hospitalizations, outpatient visits, and prescription medication use compared with matched controls. Mean annual costs for 5 years ranged from €1890 to 3010, €4867 to 5876, and €8396 to 10,001 for patients with mild, moderate, and severe SLE, respectively. CONCLUSIONS: SLE incidence in Germany increased 1.4-fold over 5 years. Patients with SLE have higher healthcare costs, and costs increase with baseline severity. Early and effective treatments may delay progression and reduce the burden of SLE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00277-0. |
format | Online Article Text |
id | pubmed-7991067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-79910672021-04-16 The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization Schwarting, Andreas Friedel, Heiko Garal-Pantaler, Elena Pignot, Marc Wang, Xia Nab, Henk Desta, Barnabas Hammond, Edward R. Rheumatol Ther Original Research INTRODUCTION: We evaluated incidence, prevalence, costs, and healthcare utilization associated with systemic lupus erythematosus (SLE) in patients in Germany. METHODS: Adult patients with SLE were identified from the German Betriebskrankenkassen (BKK) health insurance fund database between 2009 and 2014. SLE incidence and prevalence were calculated for each year and extrapolated (age and sex adjusted) to the German population. The 2009 SLE population was followed through 2014. Healthcare utilization and costs for patients with SLE were calculated and compared with controls matched by age, sex, and baseline Charlson Comorbidity Index scores. RESULTS: This analysis included 1160 patients with SLE. Estimated SLE incidence between 2009 and 2014 ranged from 4.59 to 6.89 per 100,000 persons and prevalence ranged from 37.32 to 47.36 per 100,000. SLE incidence in Germany in 2014 was 8.82 per 100,000 persons; prevalence was 55.80 (corrected for right-censored data). At baseline, 12.8, 41.7, and 45.5% of patients were categorized as having mild, moderate, and severe SLE, respectively. Patients with SLE had greater mean (standard deviation [SD]) annual medical costs compared with matched controls 1 year after index diagnosis (€6895 [14,424] vs. €3692 [3994]; P < 0.0001) and in subsequent years. Patients with moderate or severe SLE had significantly more hospitalizations, outpatient visits, and prescription medication use compared with matched controls. Mean annual costs for 5 years ranged from €1890 to 3010, €4867 to 5876, and €8396 to 10,001 for patients with mild, moderate, and severe SLE, respectively. CONCLUSIONS: SLE incidence in Germany increased 1.4-fold over 5 years. Patients with SLE have higher healthcare costs, and costs increase with baseline severity. Early and effective treatments may delay progression and reduce the burden of SLE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00277-0. Springer Healthcare 2021-02-05 /pmc/articles/PMC7991067/ /pubmed/33544369 http://dx.doi.org/10.1007/s40744-021-00277-0 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Schwarting, Andreas Friedel, Heiko Garal-Pantaler, Elena Pignot, Marc Wang, Xia Nab, Henk Desta, Barnabas Hammond, Edward R. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization |
title | The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization |
title_full | The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization |
title_fullStr | The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization |
title_full_unstemmed | The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization |
title_short | The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization |
title_sort | burden of systemic lupus erythematosus in germany: incidence, prevalence, and healthcare resource utilization |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991067/ https://www.ncbi.nlm.nih.gov/pubmed/33544369 http://dx.doi.org/10.1007/s40744-021-00277-0 |
work_keys_str_mv | AT schwartingandreas theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT friedelheiko theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT garalpantalerelena theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT pignotmarc theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT wangxia theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT nabhenk theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT destabarnabas theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT hammondedwardr theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT schwartingandreas burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT friedelheiko burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT garalpantalerelena burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT pignotmarc burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT wangxia burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT nabhenk burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT destabarnabas burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization AT hammondedwardr burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization |